Apremilast, the new drug with complex impact on inflammation in patients with psoriasis and psoriatic arthritis
2016
Abstract
Psoriasis is the systemic immunopathological disease with prevailing manifestation on the skin. This disease is characterized by the abnormal activities of Th1, Th17 and Th22 subsets of T cells.
The numerous antiinflammatory treatments are aproved for the treatment of psoriasis including biological therapy. Apremilast is newly aproved drug which is targeting phospodiesterase 4 (PDE4).
PDE4 is regulating protein kinase A. The blockade of PDE4 by apremilast is followed by the inhibition of transcription of numerous proinflammatory cytokines and mediators with the simultaneous increase in antiinflammatory IL-10 production.
The clinical response to apremilast is excellent with the minimum adverse effects.